Very low risk, low risk, or intermediate risk MDS per ipss-R

Clinical trials for Very low risk, low risk, or intermediate risk MDS per ipss-R explained in plain language.

Never miss a new study

Get alerted when new Very low risk, low risk, or intermediate risk MDS per ipss-R trials appear

Sign up with your email to follow new studies for Very low risk, low risk, or intermediate risk MDS per ipss-R, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Terminated 1

New pill aims to boost red blood cells in MDS patients

Disease control Stopped early

This phase 2 trial tested a daily pill called etavopivat in 17 adults with very low, low, or intermediate risk MDS who had anemia. The goal was to see if the drug could improve red blood cell counts and reduce the need for transfusions. The study was terminated early, so the full…

Matched conditions: VERY LOW RISK, LOW RISK, OR INTERMEDIATE RISK MDS PER IPSS-R

Phase 2 • Sponsor: Forma Therapeutics, Inc. • Aim: Disease control

Last updated Sep 05, 2026 00:00 UTC

Very low risk, low risk, or intermediate risk MDS per ipss-R

Get alerted when new Very low risk, low risk, or intermediate risk MDS per ipss-R trials appear

New pill aims to boost red blood cells in MDS patients